![Quiver Logo](/static/img/logo-icon.png)
![ACRV logo](https://quiver-logos.s3.us-east-2.amazonaws.com/acrv.png)
Acrivon Therapeutics, Inc. Common Stock
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view ACRV Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Recent trades of ACRV by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by ACRV's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Recent insights relating to ACRV
Recent picks made for ACRV stock on CNBC
ETFs with the largest estimated holdings in ACRV
Flights by private jets registered to ACRV
![Quiver Logo](/static/img/logo-icon.png)